肺癌患者血清血管内皮生长因子、内皮抑素的表达研究

The Expression of VEGF and Endostatin in Serum in Patients with Lung Cancer

目的探讨血管内皮生长因子(vascular endothelial growth factor,VEGF)、内皮抑素(En-dostatin)在肺癌患者血清中的表达以及与肺癌临床病理生理特征的关系。方法采用酶联免疫吸附法(ELISA)检测初诊肺癌患者47例及18例肺良性病变患者血清中VEGF、Endostatin的表达水平。结果肺癌患者血清中VEGF(60.93±38.23)pg/ml、Endostatin(131.71±50.32)ng/ml水平显著高于肺良性病变者(33.28±26.49)pg/ml,(85.86±36.86)ng/ml(均P(0.01);肺癌晚期、有淋巴结及远处转移及肺腺癌患者血清VEGF、Endostatin高表达。结论检测血清中VEGF及Endostatin均有助于肺癌的诊断及生物学行为的评估。

Objective To evaluate the expression of VEGF and Endostatin in serum in patients with lung cancer and to analyze the relationship between its clinical features and pathophysiological characteristics. Methods The serum samples were obtained from 47 patients with untreated primary lung cancer and 18 patients with benign pulmonary diseases. The levels of VEGF and Endostatin were analyzed by enzyme-linked immunosorbent assay （ELISA）. Results The expression of VEGF and Endostatin in sermn（60.93 ±38.23pg/ ml and 131.71 ±50.32ng/ml） in patients with lung cancer were significantly higher than those in patients with benign pulmonary diseases（33.28 ± 26.49pg/ml and 85.86 ±36.86ng/ml, respectively）, （P 〈 0.01）. The levels of VEGF and Endostatin in serum in patients with advanced stage lung cancer were higher than those of early stage patients. It was significantly higher in adenocarcinoma patients than that in patients with squamous cell carcinoma and SCLC. VEGF and Endostatin concentrations in serum were significantly higher in patients with lymph node and distant metastasis than those patients with no metastasis. Conclusion Detecting VEGF and Endostatin in serum may help to distinguish the lung cancer from benign pulmonary diseases and to reveal the biological behaviors of lung cancer.